VivoSeq
Oncology

Pancreatic Neuroendocrine Tumor

56

Pipeline Programs↗

19

Active Trials↗

20

Companies Involved↗

Pancreatic Neuroendocrine Tumor is a moderately active landscape with 56 programs across 20 companies. The most active players are Threshold Pharmaceuticals, Fresenius Kabi Oncology Ltd., Pfizer. 6 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

63/100

Pipeline Velocity

19/100

Mech. Concentration

14/100

Completion Rate

66/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

Threshold Pharmaceuticals

1 program

Phase 1F

Fresenius Kabi Oncology Ltd.

1 program

Phase 1Pfizer logo

Pfizer

2 programs

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

1 program

Phase 2Regeneron logo

Regeneron

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical3

Belzutifan

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Zanzalintinib

Merck & Co.

F18-FDG

University Health Network, Toronto

Phase 17

Fulvestrant

Fresenius Kabi Oncology Ltd.

Sandostatin LAR

Novartis

Peposertib

Merck & Co.

Fluorthanatrace

Washington University School of Medicine

Somatuline ATG

Debiopharm International SA

Phase 231

Cabozantinib

Bristol-Myers Squibb

Surufatinib

Hutchison Medipharma Limited

Temozolomide

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Ibrutinib

Pharmacyclics LLC.

Thalidomide

Bristol-Myers Squibb

Phase 39

Somatostatin

Johnson & Johnson

Everolimus

Novartis

FOLFOX

AstraZeneca

Somatostatin Analog

University of Aarhus

Long-Acting Octreotide.

Jiangsu HengRui Medicine Co., Ltd.

Approved6

Octreotide

Sun Pharma

Metformin

EMD Serono

Dacarbazine

Bayer

Chromogranin a

Asan Medical Center

Arginine/lysine

Advanced Accelerator Applications

Analysis

Modality Breakdown

82%

Small molecule

49 of 60 classified programs — the dominant modality here.

18%ALL OTHERSRadiopharmaceutical58%Peptide35%Monoclonal antibody23%Protein / enzyme12%

Small molecule leads; the ring shows all 60 classified programs, each share of the total. Modality classified for 100% of 61 pipeline programs.

Analysis

Trial Status

60

clinical trials

Completed23 · 38%
Recruiting11 · 18%
Terminated10 · 17%
Unknown status6 · 10%
Active, not recruiting5 · 8%
Not yet recruiting2 · 3%
Other3 · 5%

Clinical Trials

Trial Activity

60 trials

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT04074135·740 enrolled
A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)
Recruiting·CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logoCSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT06505395·90 enrolled
FTT PET/CT in Pancreatic Neuroendocrine Tumors
Recruiting·—·Phase 1·NCT07114939·12 enrolled
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT05687123·24 enrolled
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Recruiting·CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logoCSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2/3·NCT07165886·243 enrolled
Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors
Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT06091748·66 enrolled
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT05884255·220 enrolled
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
Recruiting·UUniversity of Chicago·Phase 1·NCT06663072·25 enrolled
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Recruiting·SWOG Cancer Research Network·Phase 2·NCT05040360·141 enrolled
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
Recruiting·National Health Research Institutes, Taiwan·Phase 1/2·NCT05048901·49 enrolled
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors
Recruiting·EExelixis·Preclinical·NCT06943755·440 enrolled
Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors
Active, not recruiting·UUniversity Health Network, Toronto·N/A·NCT04804371·40 enrolled
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors
Active, not recruiting·National Cancer Institute (NCI)·Phase 1·NCT04750954·29 enrolled
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
Active, not recruiting·Alliance for Clinical Trials in Oncology·Phase 2·NCT05247905·31 enrolled
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Active, not recruiting·ECOG-ACRIN Cancer Research Group·Phase 2·NCT01824875·144 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)